CluenexMedtronic plc MDT
Medtronic plc scores average on business quality (5.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Medtronic plc does
Medtronic manufactures medical devices, generating revenue by selling surgical tools, cardiac rhythms, and diabetes technology to hospitals and clinics globally.
- What it does best
Medtronic excels at hospital device integration, holding a 65.7% gross margin that easily outpaces peer STE at 44.4%. This edge stems from deep clinical relationships and strict regulatory approvals that make switching device vendors difficult for surgeons.
- The main risk
A 49-year dividend streak faces severe pressure as slowing revenue growth challenges cash commitments to shareholders, threatening capital allocation priorities if cash flow fails to accelerate.
Quality, check by check
Scored against its own industry, from company filings.
An operating margin of 19.9% and a net margin of 13.9% point to steady margins, though scale advantages are currently muted by high operating expenses.
High switching costs protect its hospital relationships, ranking in the middle of its sector at the 60th percentile for operating margins.
Revenue growth reached 8.4%, showing signs of acceleration compared to past annual periods as new product cycles begin to take hold.
Interest coverage of 10.3x keeps debt costs manageable alongside $6.1B in free cash flow, though net debt of $18.7B creates a heavy balance-sheet anchor.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $139K outside pre-planned sales.
Our sealed record on MDT
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Medtronic plc scores average on the Cluenex quality check (5.7 of 10), measured against its own industry. Profitability is fair, moat fair, growth steady and financial health fair.
In the last 90 days of SEC Form 4 filings: 1 sold $139K outside pre-planned sales.
Nov 16, 2026.
See MDT today
- Today's verdict on MDT, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Medtronic plc (MDT)”, https://cluenex.com/stocks/mdt/, data as of Oct 10, 2026.